An older individual suffering from hip pain.

Hip and knee osteoarthritis (OA) affects approximately 303.1 million people globally. The age-standardized prevalence, incidence, and years lived with disability have increased by 8% to 10% since 1990. This underscores the widespread impact of this degenerative joint disease on individuals’ quality of life.

To manage OA symptoms, the medical field increasingly relies on hyaluronic acid (HA) injections, a minimally invasive option to reduce pain, swelling, and stiffness. Although OA remains incurable, HA viscosupplements, like Cingal injections, have shown promising results for alleviating symptoms, especially in the knee and hip joints.

In this article, we’ll explore Cingal injections, covering their benefits for hip osteoarthritis, the injection process, expected outcomes, and real patient experiences.

Key Takeaways

  • Cingal viscosupplement leverages the effectiveness of two well-known active ingredients for osteoarthritis symptoms: hyaluronic acid (HA) and corticosteroid.
  • Cingal restores lubrication and cushioning with HA in the injections, while the corticosteroid provides an anti-inflammatory effect for immediate relief and long-lasting results for hip or knee OA.
  • The pre-injection assessment involves creating a personalized treatment plan to ensure patient safety and suitability, aligning it with their Cingal treatment.
  • Because the US Food and Drug Administration has not yet approved Cingal injections, they have not reached a broader market in the United States region.

About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. Buy Cingal online at Medica Depot today! Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.

What is Cingal and How Does it Work?

A healthcare professional holding a medical syringe.

Cingal, developed by Anika Therapeutics, is a single-injection treatment designed primarily for knee osteoarthritis (OA), though some medical professionals may recommend it off-label for hip OA. When administered appropriately, Cingal offers both immediate and long-lasting relief.

This viscosupplement harnesses the potency and properties of two known active ingredients for OA symptoms: hyaluronic acid (HA) and corticosteroid. The HA component replenishes the lost HA in the joint’s synovial fluid to restore its viscoelastic properties. In addition, the corticosteroid ingredient reduces inflammation, providing quick relief effects post-treatment.

When administered into the affected joint, Cingal restores lubrication and cushioning through the HA in the injections. At the same time, corticosteroid delivers anti-inflammatory effects for immediate relief and long-lasting hip or knee OA outcomes.

The Cingal Injection Process for Hip Pain Relief

An individual dealing with hip pain while exercising.

When considering options like Cingal vs Durolane for OA treatment, a thorough pre-injection assessment is crucial to determine the best choice for each patient. Healthcare providers begin by reviewing the patient’s medical history, OA severity, and specific treatment goals.

This evaluation may include physical examinations and imaging studies to confirm hip osteoarthritis and help design a customized treatment plan, ensuring that Cingal aligns with the patient’s needs.

  • Preparation: To minimize risk, the physician cleanses the injection site and may apply a local anesthetic for added comfort. In some cases, excess joint fluid is drained to optimize the injection’s effectiveness.
  • Administration of the Cingal Injection: Given under sterile conditions directly into the hip joint, the Cingal injection is a quick outpatient procedure, typically taking no more than an hour. This process allows patients to receive effective pain relief without extensive downtime.

Post-Injection Care and Follow-up

As Cingal delivers both immediate and long-lasting pain relief, patients are advised to follow their physician’s aftercare instructions carefully. Key steps include:

  • Resting and avoiding strenuous activities
  • Keeping the injection site clean and avoiding contact
  • Following any specific care instructions from the provider

Follow-up appointments are scheduled to monitor progress, manage any concerns, and assess recovery. Most patients experience noticeable relief within days, though individual responses vary. These check-ins ensure a safe, smooth recovery and optimal treatment outcomes.

Expected Results and Patient Experiences with Cingal Hip Injections

While there are insufficient studies and clinical data regarding Cingal hip injections, one study evaluated the efficacy of this treatment but has yet to complete and reveal the results. Nonetheless, patients are expected to receive these benefits after their treatments.

  • Improvement in Hip Joint Function and Mobility: Restoring the synovial fluid’s viscoelastic properties can enhance hip joint function, range of motion, and mobility.
  • Alleviation of Hip Pain and Discomfort: When injected into the affected hip joint, patients can expect immediate relief from the OA symptoms. This symptomatic relief can last for several months or longer.

While patient testimonials and real-life experiences from patients who have undergone Cingal injections are lacking, a patient who underwent the treatment for knee osteoarthritis shared their positive experience. They highlight the natural and effective pain relief they received immediately post-treatment.

A patient's positive experience with Cingal injection for their knee osteoarthritis.
Photo Source: Cingal

Due to the lack of approval from the US Food and Drug Administration, Cingal injections have yet to reach a wider market in the region. Individual responses may vary, and help from medical professionals can significantly affect the safety and efficacy of these treatments.

Conclusion

Cingal injections present a promising option for individuals managing hip osteoarthritis (OA), leveraging the combined effects of hyaluronic acid and corticosteroids to reduce pain and inflammation. Clinical evidence shows meaningful improvements in joint function and mobility, offering relief for many with hip OA.

While ongoing research and FDA approval are needed to confirm Cingal’s long-term efficacy and expand its market availability, its dual-action formulation provides a valuable alternative for enhancing quality of life in OA patients. Consulting with a qualified healthcare provider can help determine if Cingal is a suitable choice based on individual needs and health conditions.

FAQs

1. What is Cingal, and how does it help with hip pain?

Cingal is a single-injection treatment developed by Anika Therapeutics that combines hyaluronic acid (HA) and corticosteroids. It works by replenishing the synovial fluid in the joint, providing lubrication and cushioning while reducing inflammation, resulting in immediate and long-lasting pain relief for hip osteoarthritis.

2. What does the Cingal injection process involve?

The injection process includes a thorough assessment of the patient’s medical history and condition, preparation of the treatment area, and the administration of the injection directly into the hip joint under sterile conditions. The procedure is typically quick and performed in an outpatient setting.

3. What can patients expect after receiving a Cingal injection?

Patients often experience significant pain relief and improved joint function within a few days. While individual results may vary, many report immediate alleviation of symptoms lasting for several months. Follow-up appointments are essential to monitor recovery and address any concerns.

Require assistance or custom offers?

Our sales representatives are here to help.

BOOK A MEETING

References

  1. Safiri, S., Kolahi, A. A., Smith, E., Hill, C., Bettampadi, D., Mansournia, M. A., Hoy, D., Ashrafi-Asgarabad, A., Sepidarkish, M., Almasi-Hashiani, A., Collins, G., Kaufman, J., Qorbani, M., Moradi-Lakeh, M., Woolf, A. D., Guillemin, F., March, L., & Cross, M. (2020). Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Annals of the rheumatic diseases, 79(6), 819–828. https://doi.org/10.1136/annrheumdis-2019-216515
  2. Peck, J., Slovek, A., Miro, P., Vij, N., Traube, B., Lee, C., Berger, A. A., Kassem, H., Kaye, A. D., Sherman, W. F., & Abd-Elsayed, A. (2021). A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee. Orthopedic Reviews. https://doi.org/10.52965/001c.25549